ImmunoGen, Inc. (IMGN.W)
6.40USD
9 Feb 2010
$0.07 (+1.10%)
$6.40
--
$6.48
$6.34
420,396
527,491
$10.13
$3.85
IMGN.W
About
Overall
| Beta: | 1.65 |
| Market Cap (Mil.): | $368.26 |
| Shares Outstanding (Mil.): | 57.36 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| IMGN.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.50 | 3.76 |
| EPS (TTM): | 16.92 | -- | -- |
| ROI: | -60.68 | 1.25 | 2.30 |
| ROE: | -93.31 | 2.09 | 2.82 |
UPDATE 2-Roche restarts Phase III Avastin clinical trial
* Trial evaluates Avastin with chemotherapy in breast cancer
UPDATE 1-ImmunoGen licenses anti-cancer technology to Amgen
Nov 19 (Reuters) - Drugmaker ImmunoGen Inc said it licensed its technology to develop anti-cancer drugs to Amgen Inc for a $1 million upfront payment.
HEADLINE STOCKS-Some U.S. stocks to watch on Sept. 17
NEW YORK, Sept 17 (Reuters) - Some U.S. stocks to watch on Thursday:
UPDATE 1-ImmunoGen licenses anticancer technology to Amgen
Sept 16 (Reuters) - Drugmaker ImmunoGen Inc said it licensed its technology to develop anticancer drugs to Amgen Inc .
After Medarex buy, biotech investors ask who's next
NEW YORK (Reuters) - Investors bid up shares of Regeneron Pharmaceuticals Inc and Seattle Genetics Inc on Thursday after Medarex Inc agreed to be acquired by Bristol-Myers Squibb Co at a 90 percent premium.
After Medarex buy, biotech investors ask who's next
NEW YORK (Reuters) - Investors bid up shares of Regeneron Pharmaceuticals Inc and Seattle Genetics Inc on Thursday after Medarex Inc agreed to be acquired by Bristol-Myers Squibb Co at a 90 percent premium.
UPDATE 1-After Medarex buy, biotech investors ask who's next
* Regeneron, Seattle Genetics potential targets - analyst
UPDATE 4-Bristol-Myers to buy Medarex for $2.4 billion
* Deal would give Bristol full ownership of melanoma drug
Bristol-Myers to buy Medarex for $2.4 billion
NEW YORK (Reuters) - U.S. drugmaker Bristol-Myers Squibb Co on Wednesday said it will pay $2.4 billion to acquire Medarex Inc , a biotechnology company that has been helping it develop a promising treatment for melanoma since 2005.
Investors eye small biotech after Human Genome win
NEW YORK (Reuters) - Gambling on volatile small-cap biotechnology companies can be gut wrenching even in the best of times, but wild stock jumps based on positive clinical data may tempt investors to give them a second look with the hope of catching that really big payoff.
Competitors
| Price | Change | |
|---|---|---|
| Wyeth (WYE.N) | -- | -- |
| Wyeth (WYE_p.N) | -- | -- |
| Seattle Genetics, Inc. (SGEN.OQ) | $9.59 | +0.25 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
